PE20240357A1 - Anticuerpos anti-sema3a y usos de los mismos - Google Patents
Anticuerpos anti-sema3a y usos de los mismosInfo
- Publication number
- PE20240357A1 PE20240357A1 PE2023002753A PE2023002753A PE20240357A1 PE 20240357 A1 PE20240357 A1 PE 20240357A1 PE 2023002753 A PE2023002753 A PE 2023002753A PE 2023002753 A PE2023002753 A PE 2023002753A PE 20240357 A1 PE20240357 A1 PE 20240357A1
- Authority
- PE
- Peru
- Prior art keywords
- equal
- less
- sema3a
- seq
- sequence
- Prior art date
Links
- 102000013008 Semaphorin-3A Human genes 0.000 abstract 8
- 108010090319 Semaphorin-3A Proteins 0.000 abstract 8
- 230000027455 binding Effects 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 238000000338 in vitro Methods 0.000 abstract 3
- 238000003556 assay Methods 0.000 abstract 2
- 238000010494 dissociation reaction Methods 0.000 abstract 2
- 230000005593 dissociations Effects 0.000 abstract 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 abstract 2
- 230000012292 cell migration Effects 0.000 abstract 1
- 210000000020 growth cone Anatomy 0.000 abstract 1
- 210000003584 mesangial cell Anatomy 0.000 abstract 1
- 238000010232 migration assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a un anticuerpo aislado o fragmento de union a antigeno del mismo que se une a Sema3A humano. El anticuerpo aislado o fragmento de union a antigeno segun la presente divulgacion i) se une a Sema3A humano de la secuencia de SEQ ID NO: 600 con una constante de disociacion (KD) menor o igual a 50 nM, menor o igual a 20 nM, menor o igual a10 nM, menor o igual a 1 nM, o menor o igual a 0,1 nM; ii) reacciona cruzadamente con Sema3A de raton, cynomolgus, rata, cerdo y/o perro, particularmente en donde dicho anticuerpo aislado o fragmento de union a antigeno del mismo se une a Sema3A de raton, cynomolgus, rata, cerdo y/o perro con una constante de disociacion (KD ) menor o igual a 50 nM, menor o igual a 20 nM, menor o igual a 10 nM, menor o igual a 1 nM o menor o igual a 0,1 nM; iii) se une a Sema3A humano de la secuencia de SEQ ID NO: 600 con una actividad de union medida por resonancia de plasmon superficial (SPR) de mayor o igual a 60 %, mayor o igual a 70 %, mayor o igual a 80 % o mayor o igual a 90 %; iv) inhibe la actividad de Sema3A humana de la secuencia de SEQ ID NO: 600 en un ensayo de migracion de celulas mesangiales in vitro con una CE50 de menor o igual a 10 nM, menor o igual a 5 nM, menor o igual a 2,5 nM o menor o igual a 1 nM; v) inhibe la actividad de Sema3A humana de la secuencia de SEQ ID NO: 600 en un ensayo de colapso del cono de crecimiento in vitro con una CE50 de menor o igual a 50 nM, mrnot o igual a 25 nM, menor o igual a 10 nM o menor o igual a 5 nM; vi) inhibe la actividad de Sema3A humana de la secuencia de SEQ ID NO: 600 en un ensayo de repulsion HUVEC in vitro con una CE50 de menor o igual a 1 nM, o menor o igual a 0,3 nM, menor o igual a 0,1 nM, menor o igual a 0,07 nM, menor o igual a 0,06 nM
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21165960 | 2021-03-30 | ||
| PCT/EP2022/058123 WO2022207554A1 (en) | 2021-03-30 | 2022-03-28 | Anti-sema3a antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240357A1 true PE20240357A1 (es) | 2024-02-27 |
Family
ID=75302351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002753A PE20240357A1 (es) | 2021-03-30 | 2022-03-28 | Anticuerpos anti-sema3a y usos de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220389096A1 (es) |
| EP (1) | EP4314047A1 (es) |
| JP (1) | JP2024512633A (es) |
| KR (1) | KR20230162800A (es) |
| CN (1) | CN117396504A (es) |
| AR (1) | AR125240A1 (es) |
| AU (1) | AU2022251786A1 (es) |
| BR (1) | BR112023018061A2 (es) |
| CA (1) | CA3215274A1 (es) |
| IL (1) | IL307233A (es) |
| MX (1) | MX2023011619A (es) |
| PE (1) | PE20240357A1 (es) |
| TW (1) | TW202304975A (es) |
| WO (1) | WO2022207554A1 (es) |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
| CA2507749C (en) | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| CA2312208C (en) | 1997-12-05 | 2011-01-25 | The Scripps Research Institute | Humanization of murine antibody |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| CA2455365C (en) | 2001-08-03 | 2014-07-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
| SI2489364T1 (sl) | 2003-11-06 | 2015-04-30 | Seattle Genetics, Inc. | Monometilvalinske spojine, konjugirane s protitelesi |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US20100137156A1 (en) | 2007-03-09 | 2010-06-03 | Leung Shui-On | Construction and use of a functionally human antibody library with maximized repertoire diversity |
| JP6372040B2 (ja) | 2013-02-06 | 2018-08-15 | 公立大学法人横浜市立大学 | 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療 |
| WO2017074013A1 (ko) | 2015-10-27 | 2017-05-04 | 사회복지법인 삼성생명공익재단 | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 |
| CN113795509A (zh) * | 2019-05-09 | 2021-12-14 | 勃林格殷格翰国际有限公司 | 抗-sema3a抗体及其用于治疗眼或眼部疾病的用途 |
| WO2020261281A1 (en) * | 2019-06-27 | 2020-12-30 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
-
2022
- 2022-03-28 EP EP22713427.7A patent/EP4314047A1/en active Pending
- 2022-03-28 PE PE2023002753A patent/PE20240357A1/es unknown
- 2022-03-28 CN CN202280038261.5A patent/CN117396504A/zh active Pending
- 2022-03-28 WO PCT/EP2022/058123 patent/WO2022207554A1/en active Application Filing
- 2022-03-28 US US17/706,543 patent/US20220389096A1/en active Pending
- 2022-03-28 BR BR112023018061A patent/BR112023018061A2/pt unknown
- 2022-03-28 CA CA3215274A patent/CA3215274A1/en active Pending
- 2022-03-28 JP JP2023560024A patent/JP2024512633A/ja active Pending
- 2022-03-28 AU AU2022251786A patent/AU2022251786A1/en active Pending
- 2022-03-28 MX MX2023011619A patent/MX2023011619A/es unknown
- 2022-03-28 IL IL307233A patent/IL307233A/en unknown
- 2022-03-28 KR KR1020237036770A patent/KR20230162800A/ko unknown
- 2022-03-29 AR ARP220100753A patent/AR125240A1/es unknown
- 2022-03-30 TW TW111112217A patent/TW202304975A/zh unknown
-
2023
- 2023-12-29 US US18/399,934 patent/US20240254222A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3215274A1 (en) | 2022-10-06 |
| AU2022251786A1 (en) | 2023-10-05 |
| US20220389096A1 (en) | 2022-12-08 |
| IL307233A (en) | 2023-11-01 |
| WO2022207554A1 (en) | 2022-10-06 |
| JP2024512633A (ja) | 2024-03-19 |
| KR20230162800A (ko) | 2023-11-28 |
| AR125240A1 (es) | 2023-06-28 |
| CN117396504A (zh) | 2024-01-12 |
| BR112023018061A2 (pt) | 2023-10-03 |
| TW202304975A (zh) | 2023-02-01 |
| EP4314047A1 (en) | 2024-02-07 |
| MX2023011619A (es) | 2023-10-11 |
| US20240254222A1 (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016305697B2 (en) | Novel anti-PD-1 antibodies | |
| WO2021185273A1 (zh) | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 | |
| TWI758558B (zh) | Cd96抗體、其抗原結合片段及醫藥用途 | |
| RS54113B1 (en) | COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN | |
| WO2017024515A1 (en) | Novel anti-pd-1 antibodies | |
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| PE20140633A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| US20190256595A1 (en) | Monoclonal antibodies binding to the cd160 transmembrane isoform | |
| AR099812A1 (es) | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr | |
| AR077709A1 (es) | Anticuerpos contra el activador del receptor del ligando nf-kb humano (rankl) | |
| HRP20151213T1 (hr) | Anti-c5a protutijela i postupci za uporabu protutijela | |
| CO6612216A2 (es) | Anticuerpos completamente humanos para btla | |
| JP2016094485A (ja) | 新規モジュレータ及びその使用法 | |
| JP2017505125A5 (es) | ||
| ES2658224T3 (es) | Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos | |
| RS52804B (en) | HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND THEIR USE | |
| AR076564A1 (es) | Anticuerpos humanizados de axl(receptor de tirosina quinasa) | |
| AR065921A1 (es) | Anticuerpos anti-ige | |
| AU2005241431A1 (en) | Assay for antibodies | |
| AR111830A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| AU2015277379B2 (en) | Humanized anti-IgE antibodies that crosslink CD23 on B lymphocytes but do not sensitize mast cells | |
| CN109414499A (zh) | Ilt7结合分子及其使用方法 | |
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| WO2022166940A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| CA2795078A1 (en) | Proteins that bind pi16 and uses thereof |